Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial

American Heart Journal

Volumn 168, Issue 6, 2014, Pages 869-877.e1

  Tricoci, Pierluigi ^a   Lokhnygina, Yuliya ^a   Huang, Zhen ^a   Van De Werf, Frans ^b   Cornel, Jan H ^c   Chen, Edmond ^d,l   Wallentin, Lars ^e   Held, Claes ^e   Aylward, Philip E ^f   Moliterno, David J ^g   Jennings, Lisa K ^h   White, Harvey D ⁱ   Armstrong, Paul W ^j   Harrington, Robert A ^k   Strony, John ^d   Mahaffey, Kenneth W ^k  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Medical Centre Alkmaar   (Netherlands)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UPPSALA UNIVERSITY   (Sweden)

^f FLINDERS UNIVERSITY   (Australia)

^g UNIVERSITY OF KENTUCKY   (United States)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁱ Cardiovascular Service   (New Zealand)

^j UNIVERSITY OF ALBERTA   (Canada)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Bayer HealthCare Pharmaceuticals Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PLACEBO; VORAPAXAR; ANTITHROMBOCYTIC AGENT; LACTONE; PYRIDINE DERIVATIVE; TICLOPIDINE;

ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; RANDOMIZED CONTROLLED TRIAL; ACUTE CORONARY SYNDROME; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; DRUG MONITORING; ELECTROCARDIOGRAPHY; HEMORRHAGE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PROCEDURES; SECONDARY PREVENTION; STROKE; SURVIVAL; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; DRUG MONITORING; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HEMORRHAGE; HUMANS; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; SECONDARY PREVENTION; STROKE; SURVIVAL ANALYSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84912565436     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.09.002     Document Type: Article

References (18)

1. Leonardi S, Tricoci P, Mahaffey KW. Promises of PAR-1 inhibition in acute coronary syndrome. Curr Cardiol Rep 2012;14:32-9.
2. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:20-33.
3. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404-13.
4. TRACER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial: study design and rationale. Am Heart J 2009;158:327-34. [Erratum, Am Heart J 2010;159:932.].
5. Robins JM. Causal inference from complex longitudinal data. In: Berkane M, ed. Latent Variable Modeling and Applications to Causality: Lecture Notes in Statistics 120. New York: Springer-Verlag; 1997. p. 69-117.
6. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11:561-70.
7. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60.
8. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44-122.
9. Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015-26.
10. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010;362:1374-82.
11. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505-13.
12. Tricoci P, Roe MT, Mulgund J, et al. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med 2006;166:806-11.
13. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
14. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
15. Alexander JH, Lopes RD, James S, et al.Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708.
16. Dewilde W, Oirbans T, Verheugt F, et al. The WOEST Trial: first randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Abstract presented at the European Society of Cardiology; August 28th, 2012; Munich, Germany; 2012.. [Available at: http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=0CD0QFjAC&url=http%3A%2F%2Fwww.clinicaltrialresults.org%2FSlides%2FESC%25202012%2FTen%2520Berg-ESC%2520WOEST%25202012.ppt&ei=Qi3KUMnmBISW8gS904H4CA&usg=AFQjCNGPi4ECPVnCArk9hk5MVqYz2k74Cg&bvm=bv.1355272958,d.eWU].
17. Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet 2012;380:1317-24.
18. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011;124:544-54.